FDA Approves Transdermal Patch to Treat Alzheimer-Type Dementia

March 14, 2022

Adlarity® (donepezil transdermal system) is FDA approved to treat mild, moderate, and severe Alzheimer-type dementia. It is the first once-weekly donepezil patch approved for this use in the United States.

  • Made by Corium, Adlarity comes in 5mg/day and 10mg/day
  • Recommended initial dosing is one 5mg/day patch applied per week. If needed, the dose can be increased after 4-6 weeks to one 10mg/day patch each week.
  • Adlarity is expected to launch in the fall of Pricing is not yet available.

 

demo-attachment-261-Group-56
demo-attachment-606-Group-43
demo-attachment-1121-Rectangle-602

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager
demo-attachment-180-Group-4